Evidence map›Paper›PMID 39050990›Full record

ArticleMolecular therapy. Oncology2024

The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells.

Annalisa Carretta, Aldo Moscardini, Giovanni Signore, Doriana Debellis, Federico Catalano, Roberto Marotta, Valentina Palmieri, Giulia Tedeschi, Lorenzo Scipioni, Daniela Pozzi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Annalisa CarrettaScuola Normale Superiore, Laboratorio NEST, Piazza San Silvestro 12, 56127 Pisa, Italy.
Aldo MoscardiniScuola Normale Superiore, Laboratorio NEST, Piazza San Silvestro 12, 56127 Pisa, Italy.
Giovanni SignoreBiochemistry Unit, Department of Biology, University of Pisa, via San Zeno 51, 56123 Pisa, Italy.
Doriana DebellisElectron Microscopy Facility, Istituto Italiano di Tecnologia (IIT), Via Morego 30, 16163 Genova, Italy.
Federico CatalanoElectron Microscopy Facility, Istituto Italiano di Tecnologia (IIT), Via Morego 30, 16163 Genova, Italy.
Roberto MarottaElectron Microscopy Facility, Istituto Italiano di Tecnologia (IIT), Via Morego 30, 16163 Genova, Italy.
Valentina PalmieriIstituto dei Sistemi Complessi ISC CNR, Via dei Taurini 19, 00185 Rome, Italy.
Giulia TedeschiLaboratory for Fluorescence Dynamics, Biomedical Engineering Department, University of California, Irvine, Irvine, CA, USA.
Lorenzo ScipioniLaboratory for Fluorescence Dynamics, Biomedical Engineering Department, University of California, Irvine, Irvine, CA, USA.
Daniela PozziDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giulio CaraccioloDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Fabio BeltramScuola Normale Superiore, Laboratorio NEST, Piazza San Silvestro 12, 56127 Pisa, Italy.
Francesco CardarelliScuola Normale Superiore, Laboratorio NEST, Piazza San Silvestro 12, 56127 Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The successful trajectory of liposome-encapsulated doxorubicin (e.g., Doxil, which has been approved by the U.S. Food and Drug Administration) as an anticancer nanodrug in clinical applications is contradicted by

Indexed as

DoxildoxorubicinDoxoveselectron microscopyFLIMfluorescenceliposomal doxorubicin

Identifiers

PMID39050990
PMCPMC11268116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.